Crysvita (burosumab-twza) Treatment
ApprovedCompleted 0 watching 0 views this weekπ₯ Hot
80
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 2β
Phase 35
ApprovedIndication / Disease
Epidermal Nevus Syndrome
Conditions
Epidermal Nevus Syndrome
Trial Timeline
Jul 31, 2020 β Aug 31, 2021
NCT ID
NCT04320316About Crysvita (burosumab-twza) Treatment
Crysvita (burosumab-twza) Treatment is a approved stage product being developed by Ultragenyx Pharmaceutical for Epidermal Nevus Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04320316. Target conditions include Epidermal Nevus Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04320316 | Approved | Completed |
Competing Products
13 competing products in Epidermal Nevus Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| KRN23 | Kyowa Kirin | Phase 2 | 52 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 77 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 52 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 77 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 40 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 40 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 44 |
| ATR-04 | Azitra | Phase 1/2 | 33 |